Orlando M Gutiérrez1, Myles Wolf, Eric N Taylor. 1. Division of Nephrology, Department of Medicine, and Department of Epidemiology, University of Alabama at Birmingham, AL, USA. ogutierr@uab.edu
Abstract
BACKGROUND AND OBJECTIVES: Fibroblast growth factor 23 (FGF23) regulates phosphorus and vitamin D metabolism. Elevated FGF23 concentrations are associated with cardiovascular disease events and mortality across a broad range of kidney function, but the predictors of FGF23 concentrations in the general population are unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined cross-sectional associations of dietary and nondietary parameters with plasma FGF23 in 1261 participants of the Health Professionals Follow-up Study (mean age 64 ± 9, mean creatinine 0.9 ± 0.2 mg/dl, mean FGF23 64 ± 28 RU/ml). RESULTS: In multivariable-adjusted analyses, each 5-year increase in age was associated with 2.1 RU/ml higher FGF23, each 500-mg increase in phosphorus intake was associated with 3.4 RU/ml higher FGF23, and each 0.1-mg/dl increase in creatinine was associated with 3.4 RU/ml higher FGF23. Participants in the highest category of body mass index had 9.5 RU/ml higher FGF23 than those in the lowest, smokers had 17.1 RU/ml higher FGF23 than nonsmokers, and participants with hypertension had 6.0 RU/ml higher FGF23 than those without hypertension. With respect to biochemical parameters, higher parathyroid hormone, phosphate, uric acid, and triglyceride levels all were associated independently with higher FGF23 in models adjusted for age, creatinine, and other factors. In a subset of 748 participants with available data, some inflammatory biomarkers were associated independently with higher FGF23. CONCLUSIONS: In community-dwelling adults with largely preserved kidney function, established cardiovascular risk factors and higher phosphorus intake were associated with higher FGF23. These results might explain the link between FGF23 and cardiovascular disease.
BACKGROUND AND OBJECTIVES:Fibroblast growth factor 23 (FGF23) regulates phosphorus and vitamin D metabolism. Elevated FGF23 concentrations are associated with cardiovascular disease events and mortality across a broad range of kidney function, but the predictors of FGF23 concentrations in the general population are unclear. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined cross-sectional associations of dietary and nondietary parameters with plasma FGF23 in 1261 participants of the Health Professionals Follow-up Study (mean age 64 ± 9, mean creatinine 0.9 ± 0.2 mg/dl, mean FGF23 64 ± 28 RU/ml). RESULTS: In multivariable-adjusted analyses, each 5-year increase in age was associated with 2.1 RU/ml higher FGF23, each 500-mg increase in phosphorus intake was associated with 3.4 RU/ml higher FGF23, and each 0.1-mg/dl increase in creatinine was associated with 3.4 RU/ml higher FGF23. Participants in the highest category of body mass index had 9.5 RU/ml higher FGF23 than those in the lowest, smokers had 17.1 RU/ml higher FGF23 than nonsmokers, and participants with hypertension had 6.0 RU/ml higher FGF23 than those without hypertension. With respect to biochemical parameters, higher parathyroid hormone, phosphate, uric acid, and triglyceride levels all were associated independently with higher FGF23 in models adjusted for age, creatinine, and other factors. In a subset of 748 participants with available data, some inflammatory biomarkers were associated independently with higher FGF23. CONCLUSIONS: In community-dwelling adults with largely preserved kidney function, established cardiovascular risk factors and higher phosphorus intake were associated with higher FGF23. These results might explain the link between FGF23 and cardiovascular disease.
Authors: E Giovannucci; G Colditz; M J Stampfer; E B Rimm; L Litin; L Sampson; W C Willett Journal: Am J Epidemiol Date: 1991-04-15 Impact factor: 4.897
Authors: S Chasan-Taber; E B Rimm; M J Stampfer; D Spiegelman; G A Colditz; E Giovannucci; A Ascherio; W C Willett Journal: Epidemiology Date: 1996-01 Impact factor: 4.822
Authors: Richard Marsell; Elin Grundberg; Tijana Krajisnik; Hans Mallmin; Magnus Karlsson; Dan Mellström; Eric Orwoll; Claes Ohlsson; Kenneth B Jonsson; Osten Ljunggren; Tobias E Larsson Journal: Eur J Endocrinol Date: 2008-01 Impact factor: 6.664
Authors: Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler Journal: J Am Soc Nephrol Date: 2007-07-26 Impact factor: 10.121
Authors: Tobias Pischon; Susan E Hankinson; Gökhan S Hotamisligil; Nader Rifai; Walter C Willett; Eric B Rimm Journal: Circulation Date: 2003-06-23 Impact factor: 29.690
Authors: Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein Journal: Clin J Am Soc Nephrol Date: 2012-02-02 Impact factor: 8.237
Authors: Veronique Douard; Yves Sabbagh; Jacklyn Lee; Chirag Patel; Francis W Kemp; John D Bogden; Sheldon Lin; Ronaldo P Ferraris Journal: Am J Physiol Endocrinol Metab Date: 2013-04-09 Impact factor: 4.310
Authors: Clinton B Wright; Nirav H Shah; Armando J Mendez; Janet T DeRosa; Mitsuhiro Yoshita; Mitchell S V Elkind; Ralph L Sacco; Charles DeCarli; Tatjana Rundek; Shonni Silverberg; Chuanhui Dong; Myles Wolf Journal: Stroke Date: 2016-03-08 Impact factor: 7.914
Authors: Dominique Kosk; Holly Kramer; Amy Luke; Pauline Camacho; Pascal Bovet; Jacob Plange Rhule; Terrence Forrester; Myles Wolf; Chris Sempos; Michal L Melamed; Lara R Dugas; Richard Cooper; Ramon Durazo-Arvizu Journal: J Bone Miner Metab Date: 2016-12-09 Impact factor: 2.626